New York State Common Retirement Fund boosted its position in argenx SE (NASDAQ:ARGX) by 3.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 126,496 shares of the company’s stock after purchasing an additional 3,810 shares during the period. New York State Common Retirement Fund owned approximately 0.25% of argenx worth $34,836,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FMR LLC lifted its position in argenx by 0.6% in the fourth quarter. FMR LLC now owns 4,714,197 shares of the company’s stock worth $1,386,398,000 after purchasing an additional 28,542 shares during the period. Artisan Partners Limited Partnership increased its holdings in shares of argenx by 23.2% in the first quarter. Artisan Partners Limited Partnership now owns 2,871,989 shares of the company’s stock valued at $790,917,000 after buying an additional 540,488 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of argenx by 72.4% in the first quarter. Jennison Associates LLC now owns 719,815 shares of the company’s stock valued at $198,230,000 after buying an additional 302,188 shares in the last quarter. BlackRock Inc. increased its holdings in shares of argenx by 63.0% in the first quarter. BlackRock Inc. now owns 558,318 shares of the company’s stock valued at $153,756,000 after buying an additional 215,719 shares in the last quarter. Finally, Lone Pine Capital LLC bought a new position in shares of argenx in the fourth quarter valued at $157,708,000. Hedge funds and other institutional investors own 55.50% of the company’s stock.
NASDAQ ARGX opened at $308.90 on Friday. argenx SE has a 1-year low of $210.35 and a 1-year high of $382.15. The firm has a market capitalization of $15.85 billion, a P/E ratio of -25.49 and a beta of 0.92. The stock has a fifty day moving average of $275.99.
Several research analysts have issued reports on the company. HC Wainwright raised argenx from a “neutral” rating to a “buy” rating and upped their price target for the company from $320.00 to $400.00 in a report on Monday, May 10th. Morgan Stanley upped their price target on argenx from $321.00 to $324.00 and gave the company an “overweight” rating in a report on Tuesday, May 18th. Kepler Capital Markets cut argenx to a “hold” rating in a report on Sunday, May 16th. Zacks Investment Research downgraded shares of argenx from a “buy” rating to a “hold” rating in a research note on Tuesday, May 18th. Finally, Wedbush cut their target price on shares of argenx from $356.00 to $344.00 and set an “outperform” rating on the stock in a research note on Tuesday. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. argenx currently has a consensus rating of “Buy” and an average price target of $325.62.
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages.
Featured Story: What does an equal weight rating mean?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.